<?xml version="1.0" encoding="UTF-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /opt/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<encodingDesc>
			<appInfo>
				<application version="0.5.4" ident="GROBID" when="2019-04-16T14:13+0000">
					<ref target="https://github.com/kermitt2/grobid">GROBID - A machine learning software for extracting information from scholarly documents</ref>
				</application>
			</appInfo>
		</encodingDesc>
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Biological Crystallography Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2011">2011</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fabrice</forename><surname>Gorrec</surname></persName>
							<email>fgorrec@mrc-lmb.cam.ac.uk</email>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Acta Crystallographica Section D</orgName>
								<orgName type="laboratory" key="lab2">MRC Laboratory of Molecular Biology</orgName>
								<address>
									<addrLine>Hills Road</addrLine>
									<postCode>CB2 0QH</postCode>
									<settlement>Cambridge</settlement>
									<country>England Correspondence</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Colin</forename><forename type="middle">M</forename><surname>Palmer</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Acta Crystallographica Section D</orgName>
								<orgName type="laboratory" key="lab2">MRC Laboratory of Molecular Biology</orgName>
								<address>
									<addrLine>Hills Road</addrLine>
									<postCode>CB2 0QH</postCode>
									<settlement>Cambridge</settlement>
									<country>England Correspondence</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guillaume</forename><surname>Lebon</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Acta Crystallographica Section D</orgName>
								<orgName type="laboratory" key="lab2">MRC Laboratory of Molecular Biology</orgName>
								<address>
									<addrLine>Hills Road</addrLine>
									<postCode>CB2 0QH</postCode>
									<settlement>Cambridge</settlement>
									<country>England Correspondence</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tony</forename><surname>Warne</surname></persName>
							<affiliation key="aff0">
								<orgName type="laboratory" key="lab1">Acta Crystallographica Section D</orgName>
								<orgName type="laboratory" key="lab2">MRC Laboratory of Molecular Biology</orgName>
								<address>
									<addrLine>Hills Road</addrLine>
									<postCode>CB2 0QH</postCode>
									<settlement>Cambridge</settlement>
									<country>England Correspondence</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Biological Crystallography Pi sampling: a methodical and flexible approach to initial macromolecular crystallization screening</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Acta Cryst</title>
						<imprint>
							<biblScope unit="volume">67</biblScope>
							<biblScope unit="page" from="463" to="470"/>
							<date type="published" when="2011">2011</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1107/S0907444911008754</idno>
					<note type="submission">Received 4 January 2011 Accepted 7 March 2011</note>
					<note>research papers</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The Pi sampling method is derived from the incomplete factorial approach to macromolecular crystallization screen design. The resulting 'Pi screens' have a modular distribution of a given set of up to 36 stock solutions. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding solutions. The Pi sampling method has been implemented in a web-based application that generates screen formulations and recipes. It is particularly adapted to screens consisting of 96 different conditions. The flexibility and efficiency of Pi sampling is demonstrated by the crystallization of soluble proteins and of an integral membrane-protein sample.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>A crucial aspect of macromolecular crystallographic studies is finding suitable conditions for the crystallization of a sample. This can be difficult because many factors alter the crystallization behaviour of macromolecules, including the type and the concentration of the chemicals employed to formulate the conditions <ref type="bibr" target="#b16">(McPherson, 1990)</ref>. A condition includes at least a precipitant and most conditions also include a buffer and an additive. During the initial crystallization experiments, the structure of the macromolecule is not known and hence the most efficient formulation cannot be predicted. As a consequence, one should be cautious when making initial assumptions and limiting choices in subsequent optimizations <ref type="bibr" target="#b18">(Rupp, 2003)</ref>. Nonetheless, the number of initial crystallization conditions cannot be unreasonably large since purified protein is often difficult and expensive to produce in large quantities.</p><p>There are essentially two approaches to restrict an initial screen to a limited number of crystallization conditions. Firstly, a sparse-matrix formulation can be used, which consists of an empirically derived combination of components based on known or published crystallization conditions <ref type="bibr" target="#b9">(Jancarik &amp; Kim, 1991)</ref>. Secondly, an incomplete factorial formulation can be generated in which selected components are combined to prepare new conditions in accordance with principles of randomization and balance <ref type="bibr" target="#b3">(Carter &amp; Carter, 1979)</ref>. Numerous commercial screens based on these two main approaches are available. Automated systems have been implemented at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) to test these as routine initial screens using the 96-well crystallization plate format <ref type="bibr" target="#b20">(Stock et al., 2005)</ref>. However, for various reasons, many laboratories opt for a minimal screen <ref type="bibr" target="#b11">(Kimber et al., 2003)</ref> and still perform at least some aspects of the work manually <ref type="bibr" target="#b1">(Bergfors, 2007)</ref>.</p><p>Here, we present a development based on the incomplete factorial formulation: the Pi sampling method. The name of the method was inspired by the story of Archimedes, who used the 'method of exhaustion' (i.e. an empirical approach) with a 96-sided polygon in order to reach the first good numerical approximation of <ref type="bibr" target="#b19">(Smith, 1958)</ref>. Pi sampling uses modular arithmetic to form combinations of three stock solutions across a 96-condition grid. Maximally diverse conditions can be produced by taking into account the properties of the chemicals used in the formulation and the concentrations of the corresponding stock solutions. We have implemented this approach in a web-based application called Pi Sampler: user input consists of the details of up to 36 stock solutions, from which the application generates the formulations for a 96-condition screen. The Pi sampling method is intended to help laboratories to test new crystallization-screen formulations on a day-to-day basis based on the properties of the macromolecules investigated, as has been performed previously with RNA <ref type="bibr" target="#b6">(Doudna et al., 1993)</ref>.</p><p>Firstly, we tested Pi sampling with ten commercially available soluble proteins. For this, the 'Pi minimal screen' was employed including a wide variety of well known chemicals frequently used for macromolecular crystallization.</p><p>We then investigated the impact of Pi sampling on the crystallization of a G-protein-coupled receptor (GPCR) that had been difficult to crystallize: the adenosine A 2A receptor (construct A 2A R-GL31). We formulated another Pi screen, the 'Pi-PEG screen', taking into consideration general observations made about crystallization of integral membrane-protein samples. Previous crystallization experiments on another GPCR (the 1 -adrenergic receptor) had indicated that the use of simple proprietary screens formulated with poly(ethylene glycol) (PEG) and buffers gave a greater yield of crystals than all commercially available screens, including those geared towards membrane proteins <ref type="bibr" target="#b22">(Warne et al., 2009)</ref>, and the 2.7 A ˚ resolution structure was solved using conditions optimized from a proprietary screen essentially based on PEGs <ref type="bibr" target="#b21">(Warne et al., 2008)</ref>. This has been observed previously with other membrane-protein targets <ref type="bibr" target="#b14">(Lemieux et al., 2003)</ref>. In addition, mixtures of polyethylene glycols have been used successfully to develop a minimal screen <ref type="bibr" target="#b2">(Brzozowski &amp; Walton, 2001)</ref> and to study crystal structures of the Kir potassium channel <ref type="bibr" target="#b4">(Clarke et al., 2010)</ref>. Such mixtures were incorporated into the Pi-PEG screen.  Pi sampling: combinations of stock solutions from three different sets (see also http://pisampler.mrc-lmb.cam.ac.uk/).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 2</head><p>Pi sampling: combinations of the stock solutions in a 96-condition plate layout (well A1 is at the top left corner). Each solution of set 1 (ID 1-12) is seen in the eight conditions forming a column of the plate. The Á values of set 1 increase from left to right in the screen layout. The positions of the solutions A-L (set 2) shift across five columns and down one row (Á values not represented). The positions of solutions M-X (set 3) shift across ten columns and down one row. Gradients of concentration for sets 2 and 3 are represented on the left and right, respectively.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Pi sampling</head><p>Pi sampling begins with up to 36 stock solutions, divided into three sets of 12. The first set of solutions is used in the screen at constant concentration. The second and third sets are added according to a gradient between specified minimum and maximum concentrations. Typically, the first set is composed of buffers and the second and third sets are precipitants/ additives.</p><p>The combinations of three stock solutions (one from each set) are generated according to <ref type="figure" target="#fig_1">Fig. 1</ref>, where 1-12 refer to the IDs for solutions of the first set, A-M to those of the second set and N-X to those of the third set. The number in each cell shows which solution of the first set will be combined with the corresponding solutions of the second and third sets. Blank spaces show when no such combinations are generated. <ref type="figure">Fig. 2</ref> summarizes the distribution of the stock solutions in a standard 96-condition plate layout (i.e. 12 columns and eight rows).</p><p>Set 1: each solution (ID 1-12) is seen in the eight conditions forming a column of the plate. A variable Á should be associated with the stock solutions. The variable Á corresponds to a property of the solution selected (e.g. pH, molecular weight of the main chemical, absorption properties or others). Á values increase from left to right in the screen layout.</p><p>Set 2: each solution (ID A-L) is represented once in each row. The final concentrations decrease gradually from the top to the bottom of the screen layout, forming a gradient. The distribution of solutions A-L is based on the sequence of Á values established for set 1: the positions of the solutions shift across five columns and down one row. Solutions A-L should also be associated with a variable Á and hence a sequence is formed for the distribution of the third set of solutions.</p><p>Set 3: each solution (ID M-X) is also represented once in each row. The final concentrations increase gradually from the top to the bottom of the screen, forming another gradient. The solutions M-X are distributed with the same modulo arithmetic operation as previously, but with respect to the Á values of solutions A-L. For example, solution M is mixed with solution A in the first row, solution F in the second row, solution K in the third row and so on, as shown in <ref type="figure">Fig. 2</ref>. This means that both the second and third sets are arranged according to the same modulo arithmetic operation (5 modulo 12); however, when looking at the plate layout, the positions of solutions M-X shift across ten columns and down one row.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Pi Sampler</head><p>Pi Sampler can be accessed via the internet at http:// pisampler.mrc-lmb.cam.ac.uk/. Users can enter the details of up to 36 stock solutions, including stock concentrations, desired screen concentration ranges and Á values. The application then generates a 96-condition screen formulation following the Pi sampling method described above. Formulations, recipes and total required volumes of stock solutions are presented and may conveniently be downloaded in commaseparated variable format (CSV), allowing the user to import them into other software for automated screen making <ref type="bibr" target="#b5">(Cox &amp; Weber, 1987)</ref>, formulation analysis <ref type="bibr" target="#b8">(Hedderich et al., 2011)</ref> and data mining <ref type="bibr" target="#b10">(Kantardjieff &amp; Rupp, 2004)</ref>. The parameters used to generate the screen can also be saved and uploaded in the same format. Further details and instructions can be found on the website.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Pi minimal screen preparation and crystallization assays with commercially available soluble proteins</head><p>The final formulation of the Pi minimal screen can be found in <ref type="table">Table 1</ref>. There are 36 starting stock solutions overall. Each solution composing the first set (ID 1-12) is a mixture of an acid with its corresponding base (e.g. HEPES pH 7.5: 1 M HEPES solution mixed with 1 M HEPES sodium salt in order to reach pH 7.5), except for buffer 11 (AMPD mixed with Tris base). Note that this is also true for the precipitant phosphate (phosphate system: sodium dihydrogen phosphate/dipotassium hydrogen phosphate). Values of pH (4.0-9.5) were chosen as the variable Á for the first set, whilst arbitrary values were chosen for additives of various natures composing the second set (ID A-L). Eventually, a few conditions were made without additive/buffer because of chemical incompatibilities <ref type="table">(Table 1)</ref>.</p><p>Highest purity grade chemicals (Molecular Biology grade when available) were purchased from Sigma-Aldrich to prepare 36 stock solutions. The solutions were mixed in 96 Falcon tubes. The screen was dispensed into 'MRC original plates' (96-well, two-drop, Swissci; <ref type="bibr" target="#b20">Stock et al., 2005)</ref>.</p><p>Commercial proteins that had been crystallized before were chosen to prepare test samples. Protein concentrations were chosen randomly between 7 and 150 mg ml À1 <ref type="table" target="#tab_1">(Table 2)</ref>. Vapour-diffusion experiments were set up at 295 K, mixing two different sample: condition ratios (1:3 and 3:1) to give a final volume of 400 nl. The plates were then stored at 291 K. A condition was considered to be a hit when at least one of the two corresponding drops contained crystals with well known morphology after one week. <ref type="table" target="#tab_2">Table 3</ref> shows the 'hits per condition' observed and the corresponding results expected for the binomial distribution (see x4.2).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Pi-PEG screen preparation and crystallization assays with a GPCR</head><p>The final formulation of the Pi-PEG screen can be found in <ref type="table" target="#tab_4">Table 4</ref>. The formulation can also be generated using Pi Sampler by loading the Pi-PEG example data. The pH values (4.8-8.8) were chosen as the variable Á for the buffers composing set 1 (ID 1-12), whilst molecular weight was chosen for set 2 (PEGs A-L, final concentration range 0-22.5%). The same 12 PEGs were used for set 3 (PEGs M-X, final concentration range 0-45%). General details of the preparation are similar to x2.3, but there are 24 stock solutions at the start (instead of 36). Vapour-diffusion experiments were set up at 277 K, mixing sample and condition in a 1:1 ratio to give a final volume of 200 nl. The preparation of A 2A R-GL31 will be published elsewhere (Lebon et al., submitted work). Crystal X-ray screening was performed at the Diamond <ref type="table">Table 1</ref> Final formulation of the Pi minimal screen.</p><p>ADA, N-(2-acetamido)iminodiacetic acid; AMPD, 2-amino-2-methyl-1,3-propanediol; CAPSO, 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid; <ref type="bibr">MOPS,</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head><p>There were 116 crystallization hits overall for the experiments with the Pi minimal screen <ref type="table" target="#tab_1">(Table 2)</ref>. Some conditions produced hits for several samples <ref type="table" target="#tab_2">(Table 3)</ref>.</p><p>The Pi-PEG screen yielded crystals that diffracted to 3.0 A ˚ resolution for A 2A R-GL31 with bound agonist.      conditions is then accentuated using a number of different concentrations of solutions <ref type="figure">(Fig. 2)</ref>. If the first and second sets of solutions are ordered according to physico-chemical properties, the generated screen will be an incomplete factorial sampling of interactions between chemicals with these properties. If the chemicals selected have completely different natures, they can be arranged randomly (see x2.3). The ordering of the third set of solutions can be used to avoid obvious chemical incompatibilities (e.g. mixing phosphate and magnesium salts). It is also possible to design simpler screens with only two sets of stock solutions.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">The Pi minimal screen</head><p>In order to check the homogeneity of the hits across the screen with the ten samples, we compared the results obtained with what would be expected if each condition had the same probability of hits overall <ref type="table" target="#tab_2">(Table 3</ref>). This can be approximated by a binomial distribution. The probability of success for the binomial distribution is the observed probability for ten attempts: 116/ (10 Â 96) = 0.12083. The 2 statistic for the data is 3.48. This can be compared with the quantiles of a 2 distribution with two degrees of freedom, which gives a p value of 0.18 (calculations not shown  conditions are obvious outliers with regard to success or failure. There are, however, a multitude of possible biases implied when proceeding with crystallization experiments (which would be even more accentuated with the use of novel samples); hence, any statistical analysis should be taken with precaution. Nonetheless, it is interesting to see that the analysis of the distribution is in accordance with the original approach based on balanced randomization <ref type="bibr" target="#b3">(Carter &amp; Carter, 1979;</ref><ref type="bibr" target="#b18">Rupp, 2003)</ref>. In addition, the conditions of the Pi minimal screen show no identities to the extensive list of conditions (7230) from commercial screens stored in the 'PICKScreens' database <ref type="bibr" target="#b8">(Hedderich et al., 2011)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.">The Pi-PEG screen</head><p>The extent of effects on crystallization for precipitants such as PEGs is correlated with their concentrations <ref type="bibr" target="#b15">(McPherson, 1976</ref>) and molecular weights <ref type="bibr" target="#b7">(Forsythe et al., 2002)</ref>. The Pi-PEG screen covers a wide range of parameters (kinetics of equilibrium, protein stabilization etc.). In addition, the concentrations of the two different PEGs in a condition can be adjusted for condition optimization <ref type="bibr" target="#b20">(Stock et al., 2005)</ref> and for crystal cryoprotection <ref type="bibr" target="#b0">(Berejnov et al., 2006)</ref>. Furthermore, the PICKScreens database shows that the Pi-PEG screen is unique (as for the Pi minimal screen; see x4.2).</p><p>Samples of A 2A R-GL31 purified in a number of different detergents rarely crystallized in commercially available screens used at the LMB <ref type="bibr" target="#b20">(Stock et al., 2005)</ref> and when they did the crystal quality was not sufficient for structure determination. The first quality crystals were recently obtained using the Pi-PEG screen.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions</head><p>We have demonstrated that the Pi sampling is a methodical and flexible approach to initial screening for macromolecular crystallization. Two unique screens produced de novo have resulted from this strategy. The Pi minimal screen potentially has an ideal formulation for crystallization of novel soluble protein samples. The Pi-PEG screen is a tailor-made screen for GPCRs and potentially other membrane proteins generated by biasing the formulation towards components known to be essential.</p><p>Further screens can be formulated with the Pi Sampler on a day-to-day basis in order to test chemicals and techniques, with the aim of increasing the yield of quality crystals. Also, new crystallization techniques are constantly emerging for macromolecular targets such as membrane proteins and hence formulations with special considerations are required: one may want to formulate screens compatible with the lipidic cubic phase (LCP) concept <ref type="bibr" target="#b13">(Landau &amp; Rosenbusch, 1996)</ref> or make extensive use of detergents <ref type="bibr" target="#b12">(Koszelak-Rosenblum et al., 2009)</ref>.</p><p>In order for laboratories to be able to handle many Pi screen formulations and the flow of resulting data, we are working on the integration of Pi Sampler into the 'xtalPiMS' Laboratory Information Management System (LIMS; <ref type="bibr" target="#b17">Morris et al., 2011;</ref><ref type="bibr"></ref>  </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>et al. Pi sampling Acta Cryst. (2011). D67, 463-470</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1</head><label>1</label><figDesc>Figure 1</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>] and an example of the corresponding diffraction pattern (no cryoprotectant was required).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc>al. Pi sampling 467</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0" validated="false"><head></head><label></label><figDesc>propanesulfonic acid; PEG, poly(ethylene glycol); TAPS, N-[Tris(hydroxymethyl)- methyl]-3-aminopropanesulfonic acid.</figDesc><table>Set 1 
Set 2 
Set 3 

Well 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 

A1 
1 
Formate pH 4.0 
0.15 
M 
A 
Potassium bromide 
0.160 
M 
M 
Phosphate 
0.6 
M 
A2 
2 
Acetate pH 4.5 
0.15 
M 
B 
PEG 300 
8.000 
%(v/v) 
N 
PEG MME 550 
24.00 
%(v/v) 
A3 
3 
Malate pH 5.0 
0.15 
M 
C 
Magnesium sulfate 
0.160 
M 
O 
Ammonium nitrate 
2.0 
M 
A4 
4 
Citrate pH 5.5 
0.15 
M 
D 
Sodium fluoride 
0.032 
M 
P 
PEG 20 000 
10.0 
%(w/v) 
A5 
5 
MES pH 6.0 
0.15 
M 
E 
Potassium thiocyanate 
0.080 
M 
Q 
PEG 1000 
30.0 
%(w/v) 
A6 
6 
Cacodylate pH 6.5 
0.15 
M 
F 
Sodium iodide 
0.160 
M 
R 
Sodium chloride 
1.6 
M 
A7 
7 
MOPS pH 7.0 
0.15 
M 
G 
Propanediol 
8.000 
%(v/v) 
S 
PEG 4000 
24.0 
%(w/v) 
A8 
8 
HEPES pH 7.5 
0.15 
M 
H 
T 
Lithium sulfate 
0.8 
M 
A9 
9 
Tris pH 8.0 
0.15 
M 
I 
Ethylene glycol 
8.000 
%(v/v) 
U 
PEG MME 5000 
20.0 
%(w/v) 
A10 
10 
TAPS pH 8.5 
0.15 
M 
J 
Sodium potassium tartrate 
0.080 
M 
V 
Glycerol 
36.0 
%(w/v) 
A11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
K 
MPD 
8.000 
%(v/v) 
W 
Ammonium sulfate 
1.4 
M 
A12 
12 
CAPSO pH 9.5 
0.15 
M 
L 
2-Butanol 
8.000 
%(v/v) 
X 
PEG 8000 
20.0 
%(w/v) 
B1 
1 
Formate pH 4.0 
0.15 
M 
H 
Calcium chloride 
0.070 
M 
O 
Ammonium nitrate 
2.3 
M 
B2 
2 
Acetate pH 4.5 
0.15 
M 
I 
Ethylene glycol 
7.000 
%(v/v) 
P 
PEG 20 000 
12.0 
%(w/v) 
B3 
3 
Malate pH 5.0 
0.15 
M 
J 
Sodium potassium tartrate 
0.070 
M 
Q 
PEG 1000 
35.0 
%(w/v) 
B4 
4 
Citrate pH 5.5 
0.15 
M 
K 
MPD 
7.000 
%(v/v) 
R 
Sodium chloride 
1.8 
M 
B5 
5 
MES pH 6.0 
0.15 
M 
L 
2-Butanol 
7.000 
%(v/v) 
S 
PEG 4000 
28.0 
%(w/v) 
B6 
6 
Cacodylate pH 6.5 
0.15 
M 
A 
Potassium bromide 
0.140 
M 
T 
Lithium sulfate 
0.9 
M 
B7 
7 
MOPS pH 7.0 
0.15 
M 
B 
PEG 300 
7.000 
%(v/v) 
U 
PEG MME 5000 
23.0 
%(w/v) 
B8 
8 
HEPES pH 7.5 
0.15 
M 
C 
Magnesium sulfate 
0.140 
M 
V 
Glycerol 
42.0 
%(w/v) 
B9 
9 
Tris pH 8.0 
0.15 
M 
D 
Sodium fluoride 
0.028 
M 
W 
Ammonium sulfate 
1.6 
M 
B10 
10 
TAPS pH 8.5 
0.15 
M 
E 
Potassium thiocyanate 
0.070 
M 
X 
PEG 8000 
23.0 
%(w/v) 
B11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
F 
Sodium iodide 
0.140 
M 
M 
Phosphate 
0.7 
M 
B12 
12 
CAPSO pH 9.5 
0.15 
M 
G 
Propanediol 
7.000 
%(v/v) 
N 
PEG MME 550 
28.00 
%(v/v) 
C1 
1 
Formate pH 4.0 
0.15 
M 
C 
Magnesium sulfate 
0.120 
M 
Q 
PEG 1000 
39.0 
%(w/v) 
C2 
2 
Acetate pH 4.5 
0.15 
M 
D 
Sodium fluoride 
0.024 
M 
R 
Sodium chloride 
2.1 
M 
C3 
3 
Malate pH 5.0 
0.15 
M 
E 
Potassium thiocyanate 
0.060 
M 
S 
PEG 4000 
31.0 
%(w/v) 
C4 
4 
Citrate pH 5.5 
0.15 
M 
F 
Sodium iodide 
0.120 
M 
T 
Lithium sulfate 
1.0 
M 
C5 
5 
MES pH 6.0 
0.15 
M 
G 
Propanediol 
6.000 
%(v/v) 
U 
PEG MME 5000 
26.0 
%(w/v) 
C6 
6 
Cacodylate pH 6.5 
0.15 
M 
H 
Calcium chloride 
0.060 
M 
V 
Glycerol 
47.0 
%(w/v) 
C7 
7 
MOPS pH 7.0 
0.15 
M 
I 
Ethylene glycol 
6.000 
%(v/v) 
W 
Ammonium sulfate 
1.8 
M 
C8 
8 
HEPES pH 7.5 
0.15 
M 
J 
Sodium potassium tartrate 
0.060 
M 
X 
PEG 8000 
26.0 
%(w/v) 
C9 
9 
Tris pH 8.0 
0.15 
M 
K 
MPD 
6.000 
%(v/v) 
M 
Phosphate 
0.8 
M 
C10 
10 
TAPS pH 8.5 
0.15 
M 
L 
2-Butanol 
6.000 
%(v/v) 
N 
PEG MME 550 
31.00 
%(v/v) 
C11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
A 
Potassium bromide 
0.120 
M 
O 
Ammonium nitrate 
2.6 
M 
C12 
12 
CAPSO pH 9.5 
0.15 
M 
B 
PEG 300 
6.000 
%(v/v) 
P 
PEG 20 000 
13.0 
%(w/v) 
D1 
1 
Formate pH 4.0 
0.15 
M 
J 
S 
PEG 4000 
35.0 
%(w/v) 
D2 
2 
Acetate pH 4.5 
0.15 
M 
K 
MPD 
5.000 
%(v/v) 
T 
Lithium sulfate 
1.1 
M 
D3 
3 
Malate pH 5.0 
0.15 
M 
L 
2-Butanol 
5.000 
%(v/v) 
U 
PEG MME 5000 
38.00 
%(v/v) 
D4 
4 
Citrate pH 5.5 
0.15 
M 
A 
Potassium bromide 
0.100 
M 
V 
Glycerol 
52.0 
%(w/v) 
D5 
5 
MES pH 6.0 
0.15 
M 
B 
PEG 300 
5.000 
%(v/v) 
W 
Ammonium sulfate 
2.0 
M 
D6 
6 
Cacodylate pH 6.5 
0.15 
M 
C 
Magnesium sulfate 
0.100 
M 
X 
PEG 8000 
29.0 
%(w/v) 
D7 
7 
MOPS pH 7.0 
0.15 
M 
D 
Sodium fluoride 
0.020 
M 
M 
Phosphate 
0.9 
M 
D8 
8 
HEPES pH 7.5 
0.15 
M 
E 
Potassium thiocyanate 
0.050 
M 
N 
PEG MME 550 
34.00 
%(v/v) 
D9 
9 
Tris pH 8.0 
0.15 
M 
F 
Sodium iodide 
0.100 
M 
O 
Ammonium nitrate 
2.9 
M 
D10 
10 
TAPS pH 8.5 
0.15 
M 
G 
Propanediol 
5.000 
%(v/v) 
P 
PEG 20 000 
15.0 
%(w/v) 
D11 
11 
H 
Calcium chloride 
0.050 
M 
Q 
PEG 1000 
43.0 
%(w/v) 
D12 
12 
CAPSO pH 9.5 
0.15 
M 
I 
Ethylene glycol 
5.000 
%(v/v) 
R 
Sodium chloride 
2.3 
M 
E1 
1 
Formate pH 4.0 
0.15 
M 
E 
Potassium thiocyanate 
0.040 
M 
U 
PEG MME 5000 
32.0 
%(w/v) 
E2 
2 
Acetate pH 4.5 
0.15 
M 
F 
Sodium iodide 
0.080 
M 
V 
Glycerol 
57.0 
%(w/v) 
E3 
3 
Malate pH 5.0 
0.15 
M 
G 
Propanediol 
4.000 
%(v/v) 
W 
Ammonium sulfate 
2.2 
M 
E4 
4 
Citrate pH 5.5 
0.15 
M 
H 
X 
PEG 8000 
32.0 
%(w/v) 
E5 
5 
MES pH 6.0 
0.15 
M 
I 
Ethylene glycol 
4.000 
%(v/v) 
M 
Phosphate 
0.9 
M 
E6 
6 
Cacodylate pH 6.5 
0.15 
M 
J 
Sodium potassium tartrate 
0.040 
M 
N 
PEG MME 550 
38.0 
%(v/v) 
E7 
7 
MOPS pH 7.0 
0.15 
M 
K 
MPD 
4.000 
%(v/v) 
O 
Ammonium nitrate 
3.1 
M 
E8 
8 
HEPES pH 7.5 
0.15 
M 
L 
2-Butanol 
4.000 
%(v/v) 
P 
PEG 20 000 
16.0 
%(w/v) 
E9 
9 
Tris pH 8.0 
0.15 
M 
A 
Potassium bromide 
0.080 
M 
Q 
PEG 1000 
48.0 
%(w/v) 
E10 
10 
TAPS pH 8.5 
0.15 
M 
B 
PEG 300 
4.000 
%(v/v) 
R 
Sodium chloride 
2.5 
M 
E11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
C 
Magnesium sulfate 
0.080 
M 
S 
PEG 4000 
38.0 
%(w/v) 
E12 
12 
CAPSO pH 9.5 
0.15 
M 
D 
T 
Lithium sulfate 
1.3 
M 
F1 
1 
Formate pH 4.0 
0.15 
M 
L 
2-Butanol 
3.000 
%(v/v) 
W 
Ammonium sulfate 
2.4 
M 
F2 
2 
Acetate pH 4.5 
0.15 
M 
A 
Potassium bromide 
0.060 
M 
X 
PEG 8000 
35.0 
%(w/v) 
F3 
3 
Malate pH 5.0 
0.15 
M 
B 
PEG 300 
3.000 
%(v/v) 
M 
Phosphate 
1.0 
M 
F4 
4 
C 
Magnesium sulfate 
0.06 
M 
N 
PEG MME 550 
42.00 
%(v/v) 
F5 
5 
MES pH 6.0 
0.15 
M 
D 
Sodium fluoride 
0.012 
M 
O 
Ammonium nitrate 
3.4 
M 

synchrotron light source (microfocus 
beamline I24 equipped with a Pilatus 
6M detector). 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1" validated="true"><head>Table 2</head><label>2</label><figDesc>Details of the samples used with the Pi minimal screen(Table 1) and number of crystallization hits.</figDesc><table>TEN, buffer consisting of 20 mM 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris), 1 mM ethylene-
diaminetetraacetic acid (EDTA), 1 mM sodium azide and 200 mM sodium chloride. 

Protein 
Concentration 
(mg ml À1 ) 

MW 
(kDa) 

Source and code 
Buffer/preparation 
Hits 

Lysozyme 
10.0 
14.4 Sigma L6876 
Deionized water 
56 
Concanavalin A 
7.0 
26.5 Sigma L7647 
TEN pH 8.5 
16 
Glucose isomerase 33.0 
43.0 Hampton HR7-102 See product user guide 
11 
Xylanase 
36.0 
21.0 Hampton HR7-106 See product user guide 
8 
Ferritin 
50-150 
440.0 Fluka 96701 
As supplied by the manufacturer 
8 
Catalase 
12.6 
62.5 Sigma C3155 
Deionized water 
6 
Citrate synthase 
10.0 
49.0 Sigma C3260 
TEN pH 8.5 
5 
Lipase B 
25.0 
35.0 Hampton HR7-099 Deionized water 
4 
Ribonuclease A 
30.0 
13.7 Sigma R5503 
Deionized water 
1 
Thaumatin 
30.0 
22.0 Sigma T7638 
Deionized water 
1 
Sum 
116 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2" validated="true"><head>Table 3 '</head><label>3</label><figDesc>Hits per condition' observed and corresponding results expected with the binomial distribution (Pi minimal screen).</figDesc><table>Hits/condition 
Observed 
Expected 

0 
21 
26.5 
1 
45 
36.4 
2 
20 
22.5 
3 or more 
10 
10.6 
Sum 
96 
96 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3" validated="true"><head>Table 3 (continued)</head><label>3</label><figDesc></figDesc><table>Set 1 
Set 2 
Set 3 

Well 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 

F6 
6 
Cacodylate pH 6.5 
0.15 
M 
E 
Potassium thiocyanate 
0.030 
M 
P 
PEG 20 000 
18.0 
%(w/v) 
F7 
7 
MOPS pH 7.0 
0.15 
M 
F 
Sodium iodide 
0.060 
M 
Q 
PEG 1000 
52.0 
%(w/v) 
F8 
8 
HEPES pH 7.5 
0.15 
M 
G 
Propanediol 
3.000 
%(v/v) 
R 
Sodium chloride 
2.7 
M 
F9 
9 
Tris pH 8.0 
0.15 
M 
H 
Calcium chloride 
0.030 
M 
S 
PEG 4000 
42.0 
%(w/v) 
F10 
10 
TAPS pH 8.5 
0.15 
M 
I 
Ethylene glycol 
3.000 
%(v/v) 
T 
Lithium sulfate 
1.4 
M 
F11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
J 
Sodium potassium tartrate 
0.030 
M 
U 
PEG MME 5000 
35.0 
%(w/v) 
F12 
12 
CAPSO pH 9.5 
0.15 
M 
K 
MPD 
3.000 
%(v/v) 
V 
Glycerol 
62.0 
%(w/v) 
G1 
1 
Formate pH 4.0 
0.15 
M 
G 
Propanediol 
2.000 
%(v/v) 
M 
Phosphate 
1.1 
M 
G2 
2 
Acetate pH 4.5 
0.15 
M 
H 
N 
PEG MME 550 
45.00 
%(v/v) 
G3 
3 
Malate pH 5.0 
0.15 
M 
I 
Ethylene glycol 
2.000 
%(v/v) 
O 
Ammonium nitrate 
3.7 
M 
G4 
4 
Citrate pH 5.5 
0.15 
M 
J 
Sodium potassium tartrate 
0.020 
M 
P 
PEG 20 000 
19.0 
%(w/v) 
G5 
5 
MES pH 6.0 
0.15 
M 
K 
MPD 
2.000 
%(v/v) 
Q 
PEG 1000 
56.0 
%(w/v) 
G6 
6 
Cacodylate pH 6.5 
0.15 
M 
L 
2-Butanol 
2.000 
%(v/v) 
R 
Sodium chloride 
3.0 
M 
G7 
7 
MOPS pH 7.0 
0.15 
M 
A 
Potassium bromide 
0.040 
M 
S 
PEG 4000 
45.0 
%(w/v) 
G8 
8 
HEPES pH 7.5 
0.15 
M 
B 
PEG 300 
2.000 
%(v/v) 
T 
Lithium sulfate 
1.5 
M 
G9 
9 
Tris pH 8.0 
0.15 
M 
C 
Magnesium sulfate 
0.040 
M 
U 
PEG MME 5000 
38.0 
%(w/v) 
G10 
10 
TAPS pH 8.5 
0.15 
M 
D 
Sodium fluoride 
0.008 
M 
V 
Glycerol 
67.0 
%(w/v) 
G11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
E 
Potassium thiocyanate 
0.020 
M 
W 
Ammonium sulfate 
2.6 
M 
G12 
12 
CAPSO pH 9.5 
0.15 
M 
F 
Sodium iodide 
0.040 
M 
X 
PEG 8000 
38.0 
%(w/v) 
H1 
1 
Formate pH 4.0 
0.15 
M 
B 
PEG 300 
1.000 
%(v/v) 
O 
Ammonium nitrate 
4.0 
M 
H2 
2 
Acetate pH 4.5 
0.15 
M 
C 
Magnesium sulfate 
0.020 
M 
P 
PEG 20 000 
20.0 
%(w/v) 
H3 
3 
Malate pH 5.0 
0.15 
M 
D 
Sodium fluoride 
0.004 
M 
Q 
PEG 1000 
60.0 
%(w/v) 
H4 
4 
Citrate pH 5.5 
0.15 
M 
E 
Potassium thiocyanate 
0.010 
M 
R 
Sodium chloride 
3.2 
M 
H5 
5 
MES pH 6.0 
0.15 
M 
F 
Sodium iodide 
0.020 
M 
S 
PEG 4000 
48.0 
%(w/v) 
H6 
6 
Cacodylate pH 6.5 
0.15 
M 
G 
Propanediol 
1.000 
%(v/v) 
T 
Lithium sulfate 
1.6 
M 
H7 
7 
MOPS pH 7.0 
0.15 
M 
H 
Calcium chloride 
0.010 
M 
U 
PEG MME 5000 
40.0 
%(w/v) 
H8 
8 
HEPES pH 7.5 
0.15 
M 
I 
Ethylene glycol 
1.000 
%(v/v) 
V 
Glycerol 
72.0 
%(w/v) 
H9 
9 
Tris pH 8.0 
0.15 
M 
J 
Sodium potassium tartrate 
0.010 
M 
W 
Ammonium sulfate 
2.8 
M 
H10 
10 
TAPS pH 8.5 
0.15 
M 
K 
MPD 
1.000 
%(v/v) 
X 
PEG 8000 
40.0 
%(w/v) 
H11 
11 
AMPD/Tris pH 9.0 
0.15 
M 
L 
2-Butanol 
1.000 
%(v/v) 
M 
Phosphate 
1.2 
M 
H12 
12 
CAPSO pH 9.5 
0.15 
M 
A 
Potassium bromide 
0.020 
M 
N 
PEG MME 550 
48.00 
%(v/v) </table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4" validated="false"><head>Table 4</head><label>4</label><figDesc>Final formulation of the Pi-PEG screen.Set 1 Set 2 Set 3 Well ID Name Conc. Unit ID Name Conc. Unit ID Name Conc. Unit A1 1 Acetate pH 4.8 0.05 M A PEG 200 22.5 %(v/v) M A2 2 Acetate pH 5.2 0.05 M B PEG 300 20.0 %(v/v) N A3 3 MES pH 5.6 0.05 M C PEG MME 350 20.0 %(v/v) O A4 4 MES pH 6.0 0.05 M D PEG 400 20.0 %(v/v) P A5 5 ADA pH 6.4 0.05 M E PEG MME 550 20.0 %(v/v) Q A6 6 ADA pH 6.8 0.05 M F PEG 600 20.0 %(v/v) R A7 7 HEPES pH 7.1 0.05 M G PEG 1000 17.5 %(w/v) S A8 8 HEPES pH 7.3 0.05 M H PEG 1500 17.5 %(w/v) T A9 9 Tris pH 7.6 0.05 M I PEG 2000 15.0 %(w/v) U A10 10 Tris pH 8.0 0.05 M J PEG MME 2000 15.0 %(w/v) V A11 11 Bicine pH 8.4 0.05 M K PEG 3000 15.0 %(w/v) W A12 12 Bicine pH 8.8 0.05 M L PEG 4000 15.0 %(w/v) X B1 1 Acetate pH 4.8 0.05 M H PEG 1500 15.0 %(w/v) O PEG 4000 3.6 %(w/v) B2 2 Acetate pH 5.2 0.05 M I PEG 2000 12.9 %(w/v) P PEG 200 6.4 %(v/v) B3 3 MES pH 5.6 0.05 M J PEG MME 2000 12.9 %(w/v) Q PEG 300 5.7 %(v/v) B4 4 MES pH 6.0 0.05 M K PEG 3000 12.9 %(w/v) R PEG MME 350 5.7 %(v/v) B5 5 ADA pH 6.4 0.05 M L PEG 4000 12.9 %(w/v) S PEG 400 5.7 %(v/v) B6 6 ADA pH 6.8 0.05 M A PEG 200 19.3 %(v/v) T PEG MME 550 5.7 %(v/v) B7 7 HEPES pH 7.1 0.05 M B PEG 300 17.1 %(v/v) U PEG 600 5.7 %(v/v) B8 8 HEPES pH 7.3 0.05 M C PEG MME 350 17.1 %(v/v) V PEG 1000 5.0 %(w/v) B9 9 Tris pH 7.6 0.05 M D PEG 400 17.1 %(v/v) W PEG 1500 5.0 %(w/v) B10 10 Tris pH 8.0 0.05 M E PEG MME 550 17.1 %(v/v) X PEG 2000 4.3 %(w/v) B11 11 Bicine pH 8.4 0.05 M F PEG 600 17.1 %(v/v) M PEG MME 2000 4.3 %(w/v) B12 12 Bicine pH 8.8 0.05 M G PEG 1000 15.0 %(w/v) N PEG 3000 4.3 %(w/v) C1 1 Acetate pH 4.8 0.05 M C PEG MME 350 14.3 %(v/v) Q PEG 300 11.4 %(v/v) C2 2 Acetate pH 5.2 0.05 M D PEG 400 14.3 %(v/v) R PEG MME 350 11.4 %(v/v) C3 3 MES pH 5.6 0.05 M E PEG MME 550 14.3 %(v/v) S PEG 400 11.4 %(v/v) C4 4 MES pH 6.0 0.05 M F PEG 600 14.3 %(v/v) T PEG MME 550 11.4 %(v/v) C5 5 ADA pH 6.4 0.05 M G PEG 1000 12.5 %(w/v) U PEG 600 11.4 %(v/v) C6 6 ADA pH 6.8 0.05 M H PEG 1500 12.5 %(w/v) V PEG 1000 10.0 %(w/v) C7 7 HEPES pH 7.1 0.05 M I PEG 2000 10.7 %(w/v) W PEG 1500 10.0 %(w/v) C8 8 HEPES pH 7.3 0.05 M J PEG MME 2000 10.7 %(w/v) X PEG 2000 8.6 %(w/v) C9 9 Tris pH 7.6 0.05 M K PEG 3000 10.7 %(w/v) M PEG MME 2000 8.6 %(w/v) C10 10 Tris pH 8.0 0.05 M L PEG 4000 10.7 %(w/v) N PEG 3000 8.6 %(w/v) C11 11 Bicine pH 8.4 0.05 M A PEG 200 16.1 %(v/v) O PEG 4000 7.1 %(w/v) C12 12 Bicine pH 8.8 0.05 M B PEG 300 14.3 %(v/v) P PEG 200 12.9 %(v/v) D1 1 Acetate pH 4.8 0.05 M J PEG MME 2000 8.6 %(w/v) S PEG 400 17.1 %(w/v) D2 2 Acetate pH 5.2 0.05 M K PEG 3000 8.6 %(w/v) T PEG MME 550 17.1 %(v/v) D3 3 MES pH 5.6 0.05 M L PEG 4000 8.6 %(w/v) U PEG 600 17.1 %(v/v) D4 4 MES pH 6.0 0.05 M A PEG 200 12.9 %(v/v) V PEG 1000 15.0 %(w/v) D5 5 ADA pH 6.4 0.05 M B PEG 300 11.4 %(v/v) W PEG 1500 15.0 %(w/v) D6 6 ADA pH 6.8 0.05 M C PEG MME 350 11.4 %(v/v) X PEG 2000 12.9 %(w/v) D7 7 HEPES pH 7.1 0.05 M D PEG 400 11.4 %(v/v) M PEG MME 2000 12.9 %(w/v) D8 8 HEPES pH 7.3 0.05 M E PEG MME 550 11.4 %(v/v) N PEG 3000 12.9 %(w/v) D9 9 Tris pH 7.6 0.05 M F PEG 600 11.4 %(v/v) O PEG 4000 10.7 %(w/v) D10 10 Tris pH 8.0 0.05 M G PEG 1000 10.0 %(w/v) P PEG 200 19.3 %(v/v) D11 11 Bicine pH 8.4 0.05 M H PEG 1500 10.0 %(w/v) Q PEG 300 17.1 %(v/v) D12 12 Bicine pH 8.8 0.05 M I PEG 2000 8.6 %(w/v) R PEG MME 350 17.1 %(v/v) E1 1 Acetate pH 4.8 0.05 M E PEG MME 550 8.6 %(v/v) U PEG 600 22.9 %(v/v) E2 2 Acetate pH 5.2 0.05 M F PEG 600 8.6 %(v/v) V PEG 1000 20.0 %(w/v) E3 3 MES pH 5.6 0.05 M G PEG 1000 7.5 %(w/v) W PEG 1500 20.0 %(w/v) E4 4 MES pH 6.0 0.05 M H PEG 1500 7.5 %(w/v) X PEG 2000 17.1 %(w/v) E5 5 ADA pH 6.4 0.05 M I PEG 2000 6.4 %(w/v) M PEG MME 2000 17.1 %(w/v) E6 6 ADA pH 6.8 0.05 M J PEG MME 2000 6.4 %(w/v) N PEG 3000 17.1 %(w/v) E7 7 HEPES pH 7.1 0.05 M K PEG 3000 6.4 %(w/v) O PEG 4000 14.3 %(w/v) E8 8 HEPES pH 7.3 0.05 M L PEG 4000 6.4 %(w/v) P PEG 200 25.7 %(v/v) E9 9 Tris pH 7.6 0.05 M A PEG 200 9.6 %(v/v) Q PEG 300 22.9 %(v/v) E10 10 Tris pH 8.0 0.05 M B PEG 300 8.6 %(v/v) R PEG MME 350 22.9 %(v/v) E11 11 Bicine pH 8.4 0.05 M C PEG MME 350 8.6 %(v/v) S PEG 400 22.9 %(v/v) E12 12 Bicine pH 8.8 0.05 M D PEG 400 8.6 %(v/v) T PEG MME 550 22.9 %(v/v) F1 1 Acetate pH 4.8 0.05 M L PEG 4000 4.3 %(w/v) W PEG 1500 25.0 %(w/v) F2 2 Acetate pH 5.2 0.05 M A PEG 200 6.4 %(v/v) X PEG 2000 21.4 %(w/v) F3 3 MES pH 5.6 0.05 M B PEG 300 5.7 %(v/v) M PEG MME 2000 21.4 %(w/v) F4 4 MES pH 6.0 0.05 M C PEG MME 350 5.7 %(v/v) N PEG 3000 21.4 %(w/v) F5 5 ADA pH 6.4 0.05 M D PEG 400 5.7 %(v/v) O PEG 4000 17.9 %(w/v) F6 6 ADA pH 6.8 0.05 M E PEG MME 550 5.7 %(v/v) P PEG 200 32.1 %(v/v) F7 7 HEPES pH 7.1 0.05 M F PEG 600 5.7 %(v/v) Q PEG 300 28.6 %(v/v) F8 8 HEPES pH 7.3 0.05 M G PEG 1000 5.0 %(w/v) R PEG MME 350 28.6 %(v/v) F9 9 Tris pH 7.6 0.05 M H PEG 1500 5.0 %(w/v) S PEG 400 28.6 %(v/v) employed for the Pi sampling, it may help to imagine, on a 12 h clock, a series of events occurring every 5 h. The first event is at noon, the second at 5 pm, then 10 pm, then 3 am etc. Eventually, there is a succession of 12 events occurring at different hours, with as much time as possible in between each event. If we now look at combinations of three components, there are originally 12 3 or 1728 possibilities. Pi Sampler generates 96 of these combinations that correspond to conditions that are distant in properties. The variety between</figDesc><table>Set 1 
Set 2 
Set 3 

Well 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 

A1 
1 
Acetate pH 4.8 
0.05 
M 
A 
PEG 200 
22.5 
%(v/v) 
M 
A2 
2 
Acetate pH 5.2 
0.05 
M 
B 
PEG 300 
20.0 
%(v/v) 
N 
A3 
3 
MES pH 5.6 
0.05 
M 
C 
PEG MME 350 
20.0 
%(v/v) 
O 
A4 
4 
MES pH 6.0 
0.05 
M 
D 
PEG 400 
20.0 
%(v/v) 
P 
A5 
5 
ADA pH 6.4 
0.05 
M 
E 
PEG MME 550 
20.0 
%(v/v) 
Q 
A6 
6 
ADA pH 6.8 
0.05 
M 
F 
PEG 600 
20.0 
%(v/v) 
R 
A7 
7 
HEPES pH 7.1 
0.05 
M 
G 
PEG 1000 
17.5 
%(w/v) 
S 
A8 
8 
HEPES pH 7.3 
0.05 
M 
H 
PEG 1500 
17.5 
%(w/v) 
T 
A9 
9 
Tris pH 7.6 
0.05 
M 
I 
PEG 2000 
15.0 
%(w/v) 
U 
A10 
10 
Tris pH 8.0 
0.05 
M 
J 
PEG MME 2000 
15.0 
%(w/v) 
V 
A11 
11 
Bicine pH 8.4 
0.05 
M 
K 
PEG 3000 
15.0 
%(w/v) 
W 
A12 
12 
Bicine pH 8.8 
0.05 
M 
L 
PEG 4000 
15.0 
%(w/v) 
X 
B1 
1 
Acetate pH 4.8 
0.05 
M 
H 
PEG 1500 
15.0 
%(w/v) 
O 
PEG 4000 
3.6 
%(w/v) 
B2 
2 
Acetate pH 5.2 
0.05 
M 
I 
PEG 2000 
12.9 
%(w/v) 
P 
PEG 200 
6.4 
%(v/v) 
B3 
3 
MES pH 5.6 
0.05 
M 
J 
PEG MME 2000 
12.9 
%(w/v) 
Q 
PEG 300 
5.7 
%(v/v) 
B4 
4 
MES pH 6.0 
0.05 
M 
K 
PEG 3000 
12.9 
%(w/v) 
R 
PEG MME 350 
5.7 
%(v/v) 
B5 
5 
ADA pH 6.4 
0.05 
M 
L 
PEG 4000 
12.9 
%(w/v) 
S 
PEG 400 
5.7 
%(v/v) 
B6 
6 
ADA pH 6.8 
0.05 
M 
A 
PEG 200 
19.3 
%(v/v) 
T 
PEG MME 550 
5.7 
%(v/v) 
B7 
7 
HEPES pH 7.1 
0.05 
M 
B 
PEG 300 
17.1 
%(v/v) 
U 
PEG 600 
5.7 
%(v/v) 
B8 
8 
HEPES pH 7.3 
0.05 
M 
C 
PEG MME 350 
17.1 
%(v/v) 
V 
PEG 1000 
5.0 
%(w/v) 
B9 
9 
Tris pH 7.6 
0.05 
M 
D 
PEG 400 
17.1 
%(v/v) 
W 
PEG 1500 
5.0 
%(w/v) 
B10 
10 
Tris pH 8.0 
0.05 
M 
E 
PEG MME 550 
17.1 
%(v/v) 
X 
PEG 2000 
4.3 
%(w/v) 
B11 
11 
Bicine pH 8.4 
0.05 
M 
F 
PEG 600 
17.1 
%(v/v) 
M 
PEG MME 2000 
4.3 
%(w/v) 
B12 
12 
Bicine pH 8.8 
0.05 
M 
G 
PEG 1000 
15.0 
%(w/v) 
N 
PEG 3000 
4.3 
%(w/v) 
C1 
1 
Acetate pH 4.8 
0.05 
M 
C 
PEG MME 350 
14.3 
%(v/v) 
Q 
PEG 300 
11.4 
%(v/v) 
C2 
2 
Acetate pH 5.2 
0.05 
M 
D 
PEG 400 
14.3 
%(v/v) 
R 
PEG MME 350 
11.4 
%(v/v) 
C3 
3 
MES pH 5.6 
0.05 
M 
E 
PEG MME 550 
14.3 
%(v/v) 
S 
PEG 400 
11.4 
%(v/v) 
C4 
4 
MES pH 6.0 
0.05 
M 
F 
PEG 600 
14.3 
%(v/v) 
T 
PEG MME 550 
11.4 
%(v/v) 
C5 
5 
ADA pH 6.4 
0.05 
M 
G 
PEG 1000 
12.5 
%(w/v) 
U 
PEG 600 
11.4 
%(v/v) 
C6 
6 
ADA pH 6.8 
0.05 
M 
H 
PEG 1500 
12.5 
%(w/v) 
V 
PEG 1000 
10.0 
%(w/v) 
C7 
7 
HEPES pH 7.1 
0.05 
M 
I 
PEG 2000 
10.7 
%(w/v) 
W 
PEG 1500 
10.0 
%(w/v) 
C8 
8 
HEPES pH 7.3 
0.05 
M 
J 
PEG MME 2000 
10.7 
%(w/v) 
X 
PEG 2000 
8.6 
%(w/v) 
C9 
9 
Tris pH 7.6 
0.05 
M 
K 
PEG 3000 
10.7 
%(w/v) 
M 
PEG MME 2000 
8.6 
%(w/v) 
C10 
10 
Tris pH 8.0 
0.05 
M 
L 
PEG 4000 
10.7 
%(w/v) 
N 
PEG 3000 
8.6 
%(w/v) 
C11 
11 
Bicine pH 8.4 
0.05 
M 
A 
PEG 200 
16.1 
%(v/v) 
O 
PEG 4000 
7.1 
%(w/v) 
C12 
12 
Bicine pH 8.8 
0.05 
M 
B 
PEG 300 
14.3 
%(v/v) 
P 
PEG 200 
12.9 
%(v/v) 
D1 
1 
Acetate pH 4.8 
0.05 
M 
J 
PEG MME 2000 
8.6 
%(w/v) 
S 
PEG 400 
17.1 
%(w/v) 
D2 
2 
Acetate pH 5.2 
0.05 
M 
K 
PEG 3000 
8.6 
%(w/v) 
T 
PEG MME 550 
17.1 
%(v/v) 
D3 
3 
MES pH 5.6 
0.05 
M 
L 
PEG 4000 
8.6 
%(w/v) 
U 
PEG 600 
17.1 
%(v/v) 
D4 
4 
MES pH 6.0 
0.05 
M 
A 
PEG 200 
12.9 
%(v/v) 
V 
PEG 1000 
15.0 
%(w/v) 
D5 
5 
ADA pH 6.4 
0.05 
M 
B 
PEG 300 
11.4 
%(v/v) 
W 
PEG 1500 
15.0 
%(w/v) 
D6 
6 
ADA pH 6.8 
0.05 
M 
C 
PEG MME 350 
11.4 
%(v/v) 
X 
PEG 2000 
12.9 
%(w/v) 
D7 
7 
HEPES pH 7.1 
0.05 
M 
D 
PEG 400 
11.4 
%(v/v) 
M 
PEG MME 2000 
12.9 
%(w/v) 
D8 
8 
HEPES pH 7.3 
0.05 
M 
E 
PEG MME 550 
11.4 
%(v/v) 
N 
PEG 3000 
12.9 
%(w/v) 
D9 
9 
Tris pH 7.6 
0.05 
M 
F 
PEG 600 
11.4 
%(v/v) 
O 
PEG 4000 
10.7 
%(w/v) 
D10 
10 
Tris pH 8.0 
0.05 
M 
G 
PEG 1000 
10.0 
%(w/v) 
P 
PEG 200 
19.3 
%(v/v) 
D11 
11 
Bicine pH 8.4 
0.05 
M 
H 
PEG 1500 
10.0 
%(w/v) 
Q 
PEG 300 
17.1 
%(v/v) 
D12 
12 
Bicine pH 8.8 
0.05 
M 
I 
PEG 2000 
8.6 
%(w/v) 
R 
PEG MME 350 
17.1 
%(v/v) 
E1 
1 
Acetate pH 4.8 
0.05 
M 
E 
PEG MME 550 
8.6 
%(v/v) 
U 
PEG 600 
22.9 
%(v/v) 
E2 
2 
Acetate pH 5.2 
0.05 
M 
F 
PEG 600 
8.6 
%(v/v) 
V 
PEG 1000 
20.0 
%(w/v) 
E3 
3 
MES pH 5.6 
0.05 
M 
G 
PEG 1000 
7.5 
%(w/v) 
W 
PEG 1500 
20.0 
%(w/v) 
E4 
4 
MES pH 6.0 
0.05 
M 
H 
PEG 1500 
7.5 
%(w/v) 
X 
PEG 2000 
17.1 
%(w/v) 
E5 
5 
ADA pH 6.4 
0.05 
M 
I 
PEG 2000 
6.4 
%(w/v) 
M 
PEG MME 2000 
17.1 
%(w/v) 
E6 
6 
ADA pH 6.8 
0.05 
M 
J 
PEG MME 2000 
6.4 
%(w/v) 
N 
PEG 3000 
17.1 
%(w/v) 
E7 
7 
HEPES pH 7.1 
0.05 
M 
K 
PEG 3000 
6.4 
%(w/v) 
O 
PEG 4000 
14.3 
%(w/v) 
E8 
8 
HEPES pH 7.3 
0.05 
M 
L 
PEG 4000 
6.4 
%(w/v) 
P 
PEG 200 
25.7 
%(v/v) 
E9 
9 
Tris pH 7.6 
0.05 
M 
A 
PEG 200 
9.6 
%(v/v) 
Q 
PEG 300 
22.9 
%(v/v) 
E10 
10 
Tris pH 8.0 
0.05 
M 
B 
PEG 300 
8.6 
%(v/v) 
R 
PEG MME 350 
22.9 
%(v/v) 
E11 
11 
Bicine pH 8.4 
0.05 
M 
C 
PEG MME 350 
8.6 
%(v/v) 
S 
PEG 400 
22.9 
%(v/v) 
E12 
12 
Bicine pH 8.8 
0.05 
M 
D 
PEG 400 
8.6 
%(v/v) 
T 
PEG MME 550 
22.9 
%(v/v) 
F1 
1 
Acetate pH 4.8 
0.05 
M 
L 
PEG 4000 
4.3 
%(w/v) 
W 
PEG 1500 
25.0 
%(w/v) 
F2 
2 
Acetate pH 5.2 
0.05 
M 
A 
PEG 200 
6.4 
%(v/v) 
X 
PEG 2000 
21.4 
%(w/v) 
F3 
3 
MES pH 5.6 
0.05 
M 
B 
PEG 300 
5.7 
%(v/v) 
M 
PEG MME 2000 
21.4 
%(w/v) 
F4 
4 
MES pH 6.0 
0.05 
M 
C 
PEG MME 350 
5.7 
%(v/v) 
N 
PEG 3000 
21.4 
%(w/v) 
F5 
5 
ADA pH 6.4 
0.05 
M 
D 
PEG 400 
5.7 
%(v/v) 
O 
PEG 4000 
17.9 
%(w/v) 
F6 
6 
ADA pH 6.8 
0.05 
M 
E 
PEG MME 550 
5.7 
%(v/v) 
P 
PEG 200 
32.1 
%(v/v) 
F7 
7 
HEPES pH 7.1 
0.05 
M 
F 
PEG 600 
5.7 
%(v/v) 
Q 
PEG 300 
28.6 
%(v/v) 
F8 
8 
HEPES pH 7.3 
0.05 
M 
G 
PEG 1000 
5.0 
%(w/v) 
R 
PEG MME 350 
28.6 
%(v/v) 
F9 
9 
Tris pH 7.6 
0.05 
M 
H 
PEG 1500 
5.0 
%(w/v) 
S 
PEG 400 
28.6 
%(v/v) 

</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5" validated="false"><head></head><label></label><figDesc>). This 2 test indicates that no research papers Acta Cryst. (2011). D67, 463-470 Gorrec et al. Pi sampling 469</figDesc><table></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6" validated="false"><head>Table 4 (</head><label>4</label><figDesc>continued)</figDesc><table>Set 1 
Set 2 
Set 3 

Well 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 
ID 
Name 
Conc. 
Unit 

F10 
10 
Tris pH 8.0 
0.05 
M 
I</table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7" validated="false"><head></head><label></label><figDesc>see http://www.pims-lims.org). Thanks to Simon Byrne (Cambridge University Statistics Clinic; http://www.statslab.cam.ac.uk/clinic/) for discussions. Thanks to the LMB members Jan Lö we, John Kendrick-Jones, Christopher Aylett, Chris Tate, Jake Grimmett and Graham Lingley for various contributions. Finally, thanks to Karen Law (MRC Technology), Chris Morris (STFC, funded by CCP4) and Tanja Hedderich (Max Planck Institute). Conflicting commercial interest: we hereby state that we have a conflicting commercial interest in that MRC Technology (http://www.mrctechnology.org/) will commercialize Pi screens under an exclusive licence to Jena Bioscience (http:// www.jenabioscience.com/).</figDesc><table></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="1">research papers 468 Gorrec et al. Pi sampling Acta Cryst. (2011). D67, 463-470</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Acta Cryst. (2011). D67, 463-470</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"> <ref type="figure">Figure 3</ref> <p>Crystals of A 2A R-GL31 obtained with the Pi-PEG screen <ref type="table">(Table 4)</ref> and an example of a corresponding diffraction pattern.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Berejnov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">S</forename><surname>Husseini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">A</forename><surname>Alsaied</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Thorne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Appl. Cryst</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="244" to="251" />
			<date type="published" when="2006" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Bergfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods Mol. Biol</title>
		<imprint>
			<biblScope unit="volume">363</biblScope>
			<biblScope unit="page" from="131" to="151" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Brzozowski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Walton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Appl. Cryst</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="97" to="101" />
			<date type="published" when="2001" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Carter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="page" from="12219" to="12223" />
			<date type="published" when="1979" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">B</forename><surname>Clarke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">T</forename><surname>Caputo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">I</forename><surname>Vandenberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Gulbis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="1018" to="1029" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Weber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Appl. Cryst</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="366" to="373" />
			<date type="published" when="1987" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">A</forename><surname>Doudna</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Grosshans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Gooding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Kundrot</surname></persName>
		</author>
		<title level="m">Proc. Natl Acad. Sci. USA</title>
		<meeting>Natl Acad. Sci. USA</meeting>
		<imprint>
			<date type="published" when="1993" />
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="7829" to="7833" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">L</forename><surname>Forsythe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">L</forename><surname>Maxwell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Pusey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Cryst</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1601" to="1605" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hedderich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Marcia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kö Pke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Michel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cryst. Growth Des</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="488" to="491" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Jancarik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S.-H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Appl. Cryst</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="409" to="411" />
			<date type="published" when="1991" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">A</forename><surname>Kantardjieff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Rupp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2162" to="2168" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Kimber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Vallee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Houston</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Necakov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Skarina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Evdokimova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Beasley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Christendat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Savchenko</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">H</forename><surname>Arrowsmith</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Vedadi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Gerstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Edwards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteins</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="562" to="568" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Koszelak-Rosenblum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Krol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Mozumdar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Wunsch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ferin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">K</forename><surname>Veatch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Nagel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Luft</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">T</forename><surname>Detitta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">G</forename><surname>Malkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1828" to="1839" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">M</forename><surname>Landau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Rosenbusch</surname></persName>
		</author>
		<title level="m">Proc. Natl Acad. Sci</title>
		<meeting>Natl Acad. Sci<address><addrLine>USA, 93</addrLine></address></meeting>
		<imprint>
			<date type="published" when="1996" />
			<biblScope unit="page" from="14532" to="14535" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Lemieux</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Villa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Auer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X.-D</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D.-N</forename><surname>Wang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein Sci</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="2748" to="2756" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mcpherson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">251</biblScope>
			<biblScope unit="page" from="6300" to="6303" />
			<date type="published" when="1976" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mcpherson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Biochem</title>
		<imprint>
			<biblScope unit="volume">189</biblScope>
			<biblScope unit="page" from="1" to="23" />
			<date type="published" when="1990" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Morris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Cryst</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="249" to="260" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Rupp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Struct. Biol</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="162" to="169" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<monogr>
				<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Smith</surname></persName>
		</author>
		<title level="m">History of Mathematics</title>
		<meeting><address><addrLine>New York</addrLine></address></meeting>
		<imprint>
			<publisher>Dover Publications</publisher>
			<date type="published" when="1958" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Stock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Perisic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lö We</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Prog. Biophys. Mol. Biol</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="311" to="327" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Warne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Serrano-Vega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">G</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Moukhametzianov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">C</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">G</forename><surname>Leslie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">G</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Schertler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">454</biblScope>
			<biblScope unit="page" from="486" to="491" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title/>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Warne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">J</forename><surname>Serrano-Vega</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">G</forename><surname>Tate</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">F</forename><surname>Schertler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Protein Expr. Purif</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="204" to="213" />
			<date type="published" when="2009" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
